Vascular disease
Drug research and approvals for vascular disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 5,900 studies of vascular disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 5,900
- Trials authorized in Canada: 7
- FDA orphan approvals: 1
- EU medicines: 0
- Effect of Xylitol Chewing Gum Consumption on Coagulation Parameters and Salivary Oral Microbiological Markers in…NCT07951229 · Not applicable · Bezmialem Vakif University · starts Jul 1, 2026
- Improving Endovascular Treatment Through Process RefinementsNCT07948694 · Not applicable · Beijing Tiantan Hospital · starts Apr 15, 2026
- Follow-up of Unruptured Intracranial Aneurysms With Ultra-High Field 7 Tesla MRINCT07949903 · Not applicable · Insel Gruppe AG, University Hospital Bern · starts Dec 18, 2024
- Evalutation of Ocular Symptoms in Asymptomatic Carotid Artery StenosisNCT07949006 · Not reported · University of Bologna · starts Jan 1, 2027
- A Study to Compare the Natural History of Ataxia Telangiectasia (AT) in Children to Healthy ComparatorsNCT07948772 · Not reported · Insmed Incorporated · starts Jun 30, 2026
- Prognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial InfarctionNCT07947498 · Not applicable · Chungnam National University Hospital · starts Aug 2, 2024
- Muscle Synergy-Inspired Functional Electrical Stimulation for Rehabilitating Hand Motor Functions Post-StrokeNCT07945743 · Not applicable · Chinese University of Hong Kong · starts Nov 16, 2026
- Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling DeficitsNCT07944261 · Phase 3 · Shandong Provincial Hospital · starts Oct 15, 2026
- RDN for CKD and Uncontrolled Hypertension TrialNCT07945795 · Not applicable · Beijing Anzhen Hospital · starts Dec 8, 2025
Approved 1
- Idecabtagene vicleucelTumor necrosis factor receptor superfamily member 17 binding agent
Phase 3 8
- ChlorthalidoneThiazide-sensitive sodium-chloride cotransporter inhibitor
- AspirinCyclooxygenase inhibitor
- Vitamin e
- AmbrisentanEndothelin receptor, ET-A/ET-B antagonist
- AtenololBeta-1 adrenergic receptor antagonist
- ClopidogrelPurinergic receptor P2Y12 antagonist
- Omega-3-ACID ethyl esters
- OxygenEssential for cellular homeostasis
Phase 2 12 of 15
- AtorvastatinHMG-CoA reductase inhibitor
- EnalaprilAngiotensin-converting enzyme inhibitor
- MetoprololBeta-1 adrenergic receptor antagonist
- ReserpineSynaptic vesicular amine transporter inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- AcebutololBeta-1 adrenergic receptor antagonist
- RanolazineSodium channel protein type V alpha subunit blocker
- TriamcinoloneGlucocorticoid receptor agonist
- ColchicineTubulin inhibitor
- DoxazosinAdrenergic receptor alpha-1 antagonist
- AmlodipineVoltage-gated L-type calcium channel blocker
- Hydralazine
Phase 1 or earlier 10
- LisinoprilAngiotensin-converting enzyme inhibitor
- SimvastatinHMG-CoA reductase inhibitor
- CarvedilolAdrenergic receptor beta antagonist
- Isosorbide mononitrateSoluble guanylate cyclase activator
- Tarcocimab tedromer
- Tarcocimab
- Tedromer
- DexmedetomidineAdrenergic receptor alpha-2 agonist
- PhenylephrineAdrenergic receptor alpha-1 agonist
- ClevidipineVoltage-gated L-type calcium channel blocker
How its trials ended
1,044 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 222 whose ending is known, 45% met their primary endpoint, 8% missed it and 46% stopped early.
- Completed, result not reported42240%
- Ongoing23723%
- Status unknown16316%
- Met its primary endpoint10110%
- Stopped: other or unclear616%
- Stopped: enrollment or feasibility222%
- Missed its primary endpoint182%
- Stopped: sponsor or business decision101%
- Stopped: lack of efficacy5<1%
- Stopped: funding5<1%
| Jan 22, 2026 | A prospective, multi-national, randomized, double-blind, crossover study to evaluate the efficacy and safety of gadopiclenol-enhanced mra compared to…Gadopiclenol / Gadoterate | Guerbet | Pending |
| Dec 19, 2022 | Reexamining her cardiovascular risk - ottawa women's longitudinal cohort study (her crown)Ruby-fill | Ottawa Heart Institute Research Corporation | Ongoing |
| May 2, 2019 | A multi-center, double-blind, placebo-controlled phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved…Macitentan | Johnson & Johnson | Pending |
| Oct 10, 2014 | Perioperative ischemic evaluation-3 trial: a pilot study (POISE-3)Tranexamic acid/ Rosuvastatin | Hamilton Health Sciences Corporation | Pending |
| Feb 28, 2014 | The assessment of prednisone in remission trialPrednisone | Mount Sinai Hospital | Ongoing |
| Dec 30, 2013 | A randomized, double-blind placebo-controlled study to evaluate the effects of colchicine on vascular inflammation as assessed with positron emission…Colchicine /[18F]-fluorodeoxyglucose (18-FDG) | Montreal Heart Institute | Ongoing |
| Nov 29, 2013 | Randomized, double-blind, placebo-controlled, parallel-group study to assess cardiovascular outcomes following treatment with ertugliflozin…Ertugliflozin (MK-8835/PF-04971729) | Merck & Co. (MSD) | Closed |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Apr 14, 2000 | FlolanTreatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included… | GlaxoSmithKline | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA